Total Funding
91
82
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
7486
Naveris is a biotechnology company that provides clinically validated blood tests for the early detection of cancer.
Acquired by 
CareDx
Phil Stephens: President and Chief Scientific OfficerPast Role: Wellcome Trust Sanger Institute, Various Senior Research Positions- Piyush Gupta: Co-Founder, CEO & Chairman
About the Company
Naveris is a biotechnology company that provides highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission. The company's 3D biomimetic technology replicates the
morphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, its technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.
Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts.
